KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) EPS (Basic) (2020 - 2026)

AbCellera Biologics filings provide 7 years of EPS (Basic) readings, the most recent being -$0.14 for Q1 2026.

  • Quarterly EPS (Basic) rose 6.67% to -$0.14 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.48 through Mar 2026, up 14.29% year-over-year, with the annual reading at -$0.49 for FY2025, 10.91% up from the prior year.
  • EPS (Basic) hit -$0.14 in Q1 2026 for AbCellera Biologics, down from -$0.03 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.59 in Q1 2022 and bottomed at -$0.19 in Q3 2025.
  • Average EPS (Basic) over 5 years is -$0.07, with a median of -$0.12 recorded in 2025.
  • The largest annual shift saw EPS (Basic) skyrocketed 212.5% in 2022 before it crashed 450.0% in 2023.
  • AbCellera Biologics' EPS (Basic) stood at -$0.1 in 2022, then tumbled by 70.0% to -$0.17 in 2023, then skyrocketed by 35.29% to -$0.11 in 2024, then surged by 72.73% to -$0.03 in 2025, then tumbled by 366.67% to -$0.14 in 2026.
  • Per Business Quant, the three most recent readings for ABCL's EPS (Basic) are -$0.14 (Q1 2026), -$0.03 (Q4 2025), and -$0.19 (Q3 2025).